S. Mcfarlane
12 Papers
1 Citations
S. Mcfarlane is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 11 publications.
Chat about Author
Papers
CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease.
Christopher Ma,Jurij Hanžel,Remo Panaccione,William J. Sandborn,Geert R. D'Haens,Vineet Ahuja,Raja Atreya,Charles N. Bernstein,Peter Bossuyt,Brian Bressler,Robert V Bryant,Benjamin L Cohen,Jean-Frederic Colombel,Silvio Danese,Axel Dignass,Marla Dubinsky,Phillip Fleshner,Richard B. Gearry,Stephen B. Hanauer,Ailsa Hart,Paulo Gustavo Kotze,Torsten Kucharzik,Peter L. Lakatos,Rupert W. Leong,Fernando Magro,Julián Panés,Laurent Peyrin-Biroulet,Zhihua Ran,Miguel Regueiro,Siddharth Singh,Antonino Spinelli,A. Hillary Steinhart,Simon Travis,C. Janneke van der Woude,Bruce R. Yacyshyn,Takayuki Yamamoto,Matthieu Allez,Willem A. Bemelman,Amy L. Lightner,Edouard Louis,David T. Rubin,Ellen Scherl,Corey A. Siegel,Mark S. Silverberg,Severine Vermeire,Claire E Parker,S. Mcfarlane,Leonardo Guizzetti,Michelle I. Smith,Niels Vande Casteele,Brian G. Feagan,Vipul Jairath +51 more
TL;DR: This multidisciplinary collaboration involving patients and clinical experts has produced the first COS that can be applied to RCTs of Crohn's disease and UC.
Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score
Rish K. Pai,Vipul Jairath,M. Hogan,Guangyong Zou,Oyedele Adeyi,Quentin M. Anstee,Bashar Aqel,Cynthia Behling,Elizabeth J. Carey,Andrew D. Clouston,Kathleen E. Corey,Brian G. Feagan,David E. Kleiner,Christopher Ma,S. Mcfarlane,Mazen Noureddin,Vlad Ratziu,Mark A. Valasek,Zobair M. Younossi,Stephen A. Harrison,Rohit Loomba +20 more
TL;DR: This work evaluated the reliability of existing and alternate histologic measures and their correlations with a disease activity visual analog scale to propose optimal components for an expanded NAFLD activity score (NAS).
29
Standardizing Scoring Conventions for Crohn's Disease Endoscopy: An International RAND/UCLA Appropriateness Study.
Reena Khanna,Christopher Ma,M. Hogan,Guangyong Zou,Talat Bessissow,Brian Bressler,Jean-Frederic Colombel,Silvio Danese,Marco Daperno,James E. Fast,Lawrence Hookey,Edward V. Loftus,John W. McDonald,Remo Panaccione,Laurent Peyrin-Biroulet,Matthew D. Rutter,Bruce E. Sands,Severine Vermeire,J. Rémillard,S. Mcfarlane,William J. Sandborn,Geert R. D'Haens,Brian G. Feagan,Vipul Jairath +23 more
TL;DR: In this paper , a two-round modified Research and Development/University of California Los Angeles appropriateness methodology study was conducted, where a panel of 15 gastroenterologists used a 9-point Likert scale to rate the appropriatability of statements pertaining to the Simple Endoscopic Score for Crohn's Disease (SES-CD), Crohn’s Disease Endoscopic Index of Severity (CDEIS), and additional items relevant to endoscopy scoring in CD.
4
P268 Development and validation of a novel composite index for the assessment of endoscopic and histologic disease activity in pouchitis: The Atlantic pouchitis index
Rocio Sedano,M. Hogan,Mark S. Silverberg,Guangyong Zou,Geert R. D'Haens,J. Rémillard,S. Mcfarlane,B Bojic,Brian Bressler,Greg Rosenfeld,Roger Feakins,Richard Kirsch,A. Marchal,Mouna Adel Samaan,Remo Panaccione,Ailsa Hart,B.E. Sands,S.P.L. Travis,BG Feagan,Vipul Jairath +19 more
TL;DR: In this article , the authors developed and internally validated the Atlantic pouchitis index (API) for the assessment of endoscopic and histologic disease activity in patients with chronic antibiotic-refractory pouchitis.
P588 Interim results from the randomised VERDICT trial to determine the optimal treatment target in patients with ulcerative colitis
Vipul Jairath,Guangyong Zou,Z. Wang,Shashi Adsul,Jean-Frederic Colombel,Geert R. D'Haens,M. Freire,Gordon W. Moran,Laurent Peyrin-Biroulet,W J Sandborn,Shaji Sebastian,S.P.L. Travis,Saar Vermeire,G. Radulescu,J. P. Sigler,S. Mcfarlane,N. C. Arya,Melanie D. Beaton,Patrick M.M. Bossuyt,Dale E. Green,W. Harlan III,Marek Horynski,Maria Kłopocka,Rima Petroniene,Mark S. Silverberg,L. Wolanski,BG Feagan +26 more
TL;DR: The VERDICT trial in moderate to severe UC aims to determine if a treatment target of corticosteroid free symptomatic + endoscopic + histologic remission is superior to CS-free symptomatic remission alone as mentioned in this paper .